Overview
- Regeneron gains the exclusive opportunity to connect its genomic and proteomic data cohorts to TriNetX’s network of de-identified health records.
- The TriNetX network covers approximately 300 million de-identified patients, 170 million of them in the United States.
- Privacy-preserving matching will link a portion of the data to Regeneron Genetics Center sequencing and proteomic data under HIPAA and GDPR.
- The companies say the data will support drug discovery and future digital health solutions, including AI training.
The News
TriNetX and Regeneron Pharmaceuticals announced a strategic collaboration in April 2026 under which TriNetX will provide secure, licensed access to its current and future de-identified health data. The data comes from approximately 300 million individuals, 170 million of them in the United States, through TriNetX’s network of health system partners.
Using privacy-preserving methods, Regeneron will be able to match a portion of that data to genomic and proteomic data generated by the Regeneron Genetics Center (RGC). The companies said matching will follow applicable privacy laws, including HIPAA and GDPR. The RGC has built a large database of EHR-linked sequencing and proteomic data with over 150 collaborators worldwide.
Regeneron said the expanded database will feed its drug discovery and development and help train AI algorithms for digital health tools aimed at consumers, patients and providers. TriNetX Executive Chairman Jeff Margolis and RGC head Aris Baras, M.D., both described the deal as a way to combine research-ready health records with molecular data at scale.
Industry Perspective
Linking molecular data to longitudinal health records has become a key strategy for pharma companies seeking better targets and patient selection. These deals also renew debate about patient consent, re-identification risk and how health systems share in the value of the data their patients generate.
Strategic Impact
For TriNetX, the deal makes its federated network a key data supply to one of the largest genetics programs in the industry. For Regeneron, exclusive linkage rights could strengthen its data edge, though the value depends on how much of the network can be matched to molecular data.
Source: PRnewswire
